Retatrutide vs Wegovy: Weight Loss Comparison, Side Effects & Differences

Overview

Retatrutide and Wegovy represent two distinct pharmacological strategies for treating obesity. Wegovy (semaglutide 2.4 mg, Novo Nordisk) is an FDA-approved, once-weekly injectable GLP-1 receptor agonist specifically indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Retatrutide (LY3437943, Eli Lilly) is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, currently in Phase 3 clinical development.

The comparison between these two drugs is one of the most searched in obesity pharmacotherapy, and for good reason: Wegovy is the current benchmark for anti-obesity medication, while retatrutide’s TRIUMPH-4 Phase 3 data (-28.7% mean weight loss at 68 weeks) suggest it may substantially surpass that benchmark. Understanding the differences between these agents — in mechanism, efficacy, safety, and availability — is essential context for patients, clinicians, and the broader medical community.

Important note: No head-to-head clinical trial has directly compared retatrutide to Wegovy. All efficacy comparisons presented here are cross-trial observations subject to significant limitations including differences in study populations, trial design, duration, and outcome measurement. These comparisons are for educational context only and should not be interpreted as definitive evidence of relative efficacy.

Mechanism of Action

Wegovy (Semaglutide 2.4 mg)

Wegovy contains semaglutide, a selective GLP-1 receptor agonist with 94% structural homology to native human GLP-1. It acts exclusively through GLP-1 receptor-mediated pathways to achieve weight loss:

• Centrally mediated appetite suppression via hypothalamic and brainstem GLP-1 receptors, leading to reduced hunger and increased satiety
• Delayed gastric emptying, contributing to prolonged fullness after meals
• Glucose-dependent insulin secretion and glucagon suppression
• Potential cardiovascular protective effects through direct vascular GLP-1R signaling

The 2.4 mg dose used in Wegovy is higher than the 1.0 mg dose used in Ozempic (the diabetes-indicated brand), optimized specifically for weight management. The molecule is identical in both products; only the dosage and approved indication differ. A C18 fatty diacid modification extends its half-life to approximately 7 days, enabling once-weekly dosing.

Retatrutide

Retatrutide engages three distinct receptor pathways simultaneously. In addition to the GLP-1 receptor effects shared with Wegovy, retatrutide activates:

• GIP receptors, which contribute to adipose tissue remodeling, enhanced insulin secretion, and potentially additional central appetite regulation. GIP receptor activation may also modulate gastrointestinal motility in a way that partially mitigates GLP-1-driven nausea.
• Glucagon receptors, which increase hepatic energy expenditure, promote fatty acid oxidation, and stimulate thermogenesis. This is the critical differentiator — the glucagon component drives calorie burning rather than solely reducing calorie intake.

This triple mechanism creates a fundamentally different pharmacological profile. While Wegovy reduces energy intake through appetite suppression, retatrutide both reduces energy intake (via GLP-1R and GIPR) and increases energy expenditure (via GCGR), producing a larger net energy deficit.

Why the Mechanism Difference Matters Clinically

The clinical significance of this mechanistic distinction becomes apparent when considering the weight loss plateau. With Wegovy, weight loss typically plateaus around 60-68 weeks as the body’s metabolic adaptation (reduced resting metabolic rate) counterbalances the appetite suppression. Retatrutide’s glucagon component directly opposes this metabolic adaptation by maintaining elevated energy expenditure. This may explain why retatrutide’s Phase 2 weight loss curve had not plateaued at 48 weeks, and why the Phase 3 TRIUMPH-4 results exceeded Phase 2 data rather than falling short.

Retatrutide is a 39-amino-acid synthetic peptide with a molecular weight of approximately 4,731 Da. Like Wegovy, it uses fatty acid acylation (C20) for albumin binding and half-life extension (~6 days), enabling once-weekly subcutaneous injection.

Efficacy Comparison

Weight Loss

The weight loss data from clinical trials show a substantial numerical difference between the two agents:

Parameter	Wegovy (Semaglutide 2.4 mg)	Retatrutide 12 mg (Phase 2)	Retatrutide (TRIUMPH-4, Phase 3)
Trial	STEP 1 (Phase 3)	Phase 2 obesity	TRIUMPH-4 (Phase 3)
Duration	68 weeks	48 weeks	48 weeks
Population	BMI ≥30 or ≥27 with comorbidity	Obesity/overweight	Obesity/overweight
Mean weight loss	-14.9%	-24.2%	-28.7%
≥5% weight loss	~86%	~100%	Data pending
≥10% weight loss	~70%	~93%	Data pending
≥15% weight loss	~50%	~83%	Data pending
≥20% weight loss	~32%	~73%	Data pending

The TRIUMPH-4 Phase 3 result of -28.7% mean weight loss at 68 weeks is the most striking data point in this comparison. It represents nearly double the weight loss achieved by Wegovy (-14.9%) despite a shorter treatment duration (48 vs. 68 weeks). For context, this means an average participant weighing 100 kg at baseline would lose approximately 28.7 kg on retatrutide versus approximately 14.9 kg on Wegovy.

Significance of the Phase 3 Confirmation

The TRIUMPH-4 results carry more evidentiary weight than Phase 2 data for a critical reason: Phase 3 trials enroll larger, more diverse populations under conditions closer to real-world clinical practice. Phase 2 results routinely overperform relative to Phase 3 — smaller sample sizes, more selected patients, and tighter protocol adherence all bias toward stronger efficacy signals. The fact that retatrutide’s Phase 3 data (-28.7%) exceeded its Phase 2 data (-24.2%) is unusual and strengthens confidence in the drug’s clinical profile.

Weight Loss Trajectory

Wegovy’s weight loss in STEP 1 appeared to approach a plateau around 60 to 68 weeks. Retatrutide’s Phase 2 data at 48 weeks showed a trajectory that was still declining, with participants continuing to lose weight at the final assessment. This difference in trajectory may be attributable to the glucagon receptor-mediated increase in energy expenditure, which could sustain weight loss beyond what appetite suppression alone achieves.

If retatrutide’s weight loss continues beyond 48 weeks without plateau — as the trajectory suggests it might — the ultimate magnitude of weight loss could approach or exceed 30%, a level previously achieved only through bariatric surgery.

Liver Fat Reduction

This is one of the most clinically important areas of differentiation:

Parameter	Wegovy	Retatrutide
Relative liver fat reduction	~40-50% (from semaglutide MASLD studies)	~82% (Phase 2)
Primary mechanism	Indirect: weight loss, insulin sensitivity	Direct: GCGR-mediated hepatic fatty acid oxidation + indirect
Clinical significance	Modest MASLD improvement	Potentially transformative for MASLD/MASH

The approximately 30-40 percentage point difference in liver fat reduction is one of the clearest mechanistic differentiators between these agents. Retatrutide’s glucagon receptor component directly instructs hepatocytes to oxidize stored triglycerides — a pharmacological effect that Wegovy, lacking glucagon activity, cannot replicate regardless of dose.

Safety Comparison

Gastrointestinal Effects

Both agents share GLP-1 receptor-driven gastrointestinal adverse events, which are the most commonly reported side effects:

Adverse Event	Wegovy (STEP 1)	Retatrutide 12 mg (Phase 2)
Nausea	~44%	~24%
Diarrhea	~30%	~22%
Vomiting	~24%	~13%
Constipation	~24%	~12%

Notably, retatrutide showed numerically lower GI event rates in Phase 2 despite greater weight loss. This could reflect differences in dose-escalation protocols, the modulatory effects of GIP receptor activation on GI tolerability, or differences in how adverse events were captured across trials. Phase 3 data will provide a more reliable safety profile.

GI adverse events with both drugs are typically:

• Most pronounced during dose escalation (first 4-8 weeks)
• Mild to moderate in severity for the majority of patients
• Transient, improving with continued treatment
• Manageable through dietary modifications (smaller meals, avoiding high-fat foods)

Cardiovascular Considerations

Wegovy has a significant advantage in cardiovascular evidence. The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in adults with overweight or obesity and established cardiovascular disease. This landmark result led to an expanded FDA indication for cardiovascular risk reduction and represents one of the most important clinical differentiators in Wegovy’s favor.

Retatrutide has no cardiovascular outcomes data. While Phase 2 results showed improvements in cardiovascular risk factors (blood pressure reductions, favorable lipid changes), dedicated outcomes trials would be needed to establish cardiovascular safety or benefit. Given that cardiovascular disease is the leading cause of death in people with obesity, this evidence gap is clinically meaningful.

Heart Rate and Blood Pressure

Both agents increase heart rate modestly (2-4 bpm), a GLP-1R class effect. Both produce blood pressure reductions, likely driven by weight loss and potentially direct vascular effects. Retatrutide’s glucagon component may contribute additional hemodynamic effects, though the clinical significance is unclear from current data.

Gallbladder Events

Rapid weight loss from any cause increases the risk of gallstone formation (cholelithiasis) and gallbladder inflammation (cholecystitis). This is not a drug-specific effect but a consequence of rapid mobilization of cholesterol during fat metabolism. Wegovy’s STEP trials reported gallbladder events in approximately 1.5-2.5% of patients. Retatrutide’s greater weight loss magnitude could theoretically increase this risk, and Phase 3 monitoring of gallbladder events will be important.

Pancreatitis

Both drugs carry warnings about potential pancreatitis risk, a class concern with incretin-based therapies. Rates are low (<1%) with semaglutide in large Phase 3 and real-world datasets. Phase 2 data for retatrutide did not show an elevated pancreatitis signal, but larger Phase 3 populations provide more power to detect this rare event.

Thyroid Considerations

Wegovy carries a boxed warning for thyroid C-cell tumor risk based on rodent studies with GLP-1 receptor agonists. The clinical relevance in humans remains unestablished after years of monitoring. Retatrutide’s thyroid safety profile in humans is being characterized in the Phase 3 program.

Body Composition Considerations

With weight loss exceeding 25%, body composition becomes a critical concern. Not all weight loss is equal — losing fat mass improves metabolic health, while losing lean mass (muscle, bone) can impair physical function, reduce metabolic rate, and increase frailty risk.

Wegovy

Body composition data from the STEP trials show that approximately 60-70% of weight lost with Wegovy is fat mass, with 30-40% lean mass. This ratio is consistent with caloric restriction-driven weight loss and has been a point of discussion in the clinical community. At 15% total weight loss, the absolute lean mass loss is moderate and generally well-tolerated, particularly in younger patients.

Retatrutide

Retatrutide’s body composition data are still being characterized in Phase 3. Two competing mechanisms affect lean mass: glucagon receptor activation stimulates amino acid catabolism (potentially increasing lean mass loss) but also strongly drives fatty acid oxidation (potentially shifting energy substrate use toward fat and away from protein). The net effect at -28.7% weight loss is an important outstanding question.

At the magnitude of weight loss retatrutide achieves, even a proportionally similar lean-to-fat ratio means substantially more absolute lean mass loss. For a 100 kg patient losing 28.7 kg, approximately 9-11 kg could be lean mass — enough to warrant attention.

Practical Mitigation

For both drugs, clinical guidelines increasingly recommend:

• Adequate protein intake (≥1.2-1.6 g/kg/day of ideal body weight)
• Resistance exercise at least 2-3 times per week
• Monitoring of functional capacity and muscle strength during treatment
• Bone density assessment in at-risk populations

Dose Titration and Practical Use

Wegovy Dosing

Wegovy uses a well-established 16-20 week dose-escalation protocol: 0.25 mg weekly for 4 weeks, then 0.5 mg, 1.0 mg, and 1.7 mg for 4 weeks each, followed by the maintenance dose of 2.4 mg. This gradual escalation significantly reduces GI side effects during initiation. The protocol has been refined through extensive clinical experience and is well-understood by prescribers.

Wegovy is administered via a prefilled pen injector, designed for patient self-administration at home. The injection sites (abdomen, thigh, upper arm) are rotated weekly. Supply stability has improved after shortages in 2023-2024, though availability varies by region.

Retatrutide Dosing

Retatrutide’s dose-escalation protocol in clinical trials targets the 12 mg maintenance dose. The specific titration schedule optimized for Phase 3 likely contributed to the improved results seen in TRIUMPH-4 compared to Phase 2. Once approved, the prescribing information will define the titration protocol for clinical use.

Both drugs require once-weekly subcutaneous injection — a practically equivalent administration burden.

Patient Population-Specific Considerations

Severe Obesity (BMI ≥40)

For patients with severe obesity, the magnitude difference between Wegovy (-14.9%) and retatrutide (-28.7%) is particularly consequential. A patient with a starting weight of 140 kg would lose approximately 21 kg on Wegovy versus approximately 40 kg on retatrutide. The latter approaches the range typically associated with bariatric surgery and could mean the difference between modest improvement and transformative clinical outcomes — resolution of sleep apnea, diabetes remission, restored mobility, and reduced need for joint replacement.

MASLD/MASH

The liver fat data strongly favor retatrutide for patients with metabolic dysfunction-associated steatotic liver disease. The ~82% relative liver fat reduction versus ~40-50% could mean the difference between partial improvement and near-complete resolution of hepatic steatosis. Given that MASLD affects approximately 25-30% of adults globally and is the fastest-growing cause of liver transplantation, this differentiation has significant public health implications.

Cardiovascular Disease

Wegovy has a proven cardiovascular advantage through the SELECT trial (20% MACE reduction). For patients with established cardiovascular disease or high cardiovascular risk, Wegovy remains the evidence-based choice until retatrutide generates comparable outcomes data.

Post-Bariatric Surgery

An emerging clinical question is whether pharmacotherapy can supplement bariatric surgery outcomes. Some patients regain weight after surgery, and Wegovy has shown benefit in this population. Retatrutide has not been studied in post-surgical patients, but its greater weight loss magnitude makes it a candidate for future evaluation in this setting.

Key Differences Summary

Feature	Wegovy	Retatrutide
Receptor targets	GLP-1 only	GIP + GLP-1 + Glucagon
Molecular weight	~4,114 Da	~4,731 Da
Approval status	FDA-approved (2021)	Investigational (Phase 3)
Indication	Chronic weight management, CV risk	Not yet approved
Manufacturer	Novo Nordisk	Eli Lilly
Administration	Once-weekly SC injection	Once-weekly SC injection
Weight loss (Phase 3, cross-trial)	-14.9% at 68 weeks	-28.7% at 68 weeks
Liver fat reduction	~40-50%	~82%
CV outcomes data	Yes (SELECT trial)	No
Real-world experience	Extensive (millions of patients)	None
Mechanism of weight loss	Appetite suppression	Appetite suppression + increased energy expenditure
Expected cost	~$1,300/month (list price)	Unknown

Status and Availability

Parameter	Wegovy	Retatrutide
FDA approval	Approved June 2021	Not approved
Current phase	Post-marketing	Phase 3 (TRIUMPH program)
Phase 3 weight loss confirmed	Yes	Yes (TRIUMPH-4: -28.7%)
Cardiovascular indication	Yes (SELECT, 2024)	Not studied
Prescribable	Yes	No (clinical trials only)
Expected availability	Now	Earliest late 2027-2028
Supply situation	Improving after shortages	Not applicable
Oral formulation	Available (Rybelsus, lower dose)	Not in development
Insurance coverage	Variable, expanding	Not applicable

The practical reality is straightforward: Wegovy is available now, with an established prescribing framework, insurance coverage (where applicable), and years of real-world experience informing its use. Retatrutide is 2-3 years from the earliest possible approval. Patients making treatment decisions today should consider Wegovy and other approved options rather than waiting for retatrutide.

Cost, Insurance, and Access

Wegovy

Wegovy’s list price is approximately $1,300 per month. Insurance coverage has expanded since its initial approval but remains inconsistent. Medicare Part D coverage for anti-obesity medications is evolving, and many private insurers still restrict coverage or impose prior authorization requirements. Patient assistance programs and manufacturer savings cards help bridge some of the gap. The cost burden is a significant factor in treatment adherence and access.

Retatrutide

Retatrutide’s pricing is unknown, but several factors will influence its market positioning:

• If Eli Lilly prices it at a premium to tirzepatide (reflecting greater efficacy), the monthly cost could exceed $1,500
• Greater weight loss may improve cost-effectiveness if it produces proportionally better clinical outcomes
• Insurance coverage will depend on the approved indications and the strength of the clinical evidence package
• Competition with CagriSema and next-generation GLP-1 agonists could moderate pricing

The economics of obesity treatment are shifting. As evidence accumulates that pharmacological weight loss reduces long-term healthcare costs (fewer cardiovascular events, diabetes complications, joint replacements, and cancer diagnoses), payer resistance to coverage is gradually decreasing.

Long-Term Durability and Weight Regain

A critical question for both drugs is the durability of weight loss and what happens upon discontinuation.

Wegovy: The STEP 1 trial extension and STEP 4 withdrawal study demonstrated significant weight regain after semaglutide discontinuation — patients regained approximately two-thirds of lost weight within one year. This establishes that Wegovy requires chronic, ongoing use to maintain benefit. It is not a “course of treatment” that can be completed and stopped; it is a continuous therapy analogous to blood pressure medication.

Retatrutide: No discontinuation data are available. The glucagon receptor component raises an interesting question: if GCGR-mediated changes in hepatic metabolism or energy expenditure produce lasting metabolic adaptations, some degree of sustained benefit after discontinuation might be possible. However, this is entirely speculative. The most prudent assumption is that retatrutide, like all incretin-based therapies, will require chronic use.

The implication for the comparison is that long-term cost, tolerability, and safety become even more important than acute efficacy. A drug that produces 28.7% weight loss but must be taken indefinitely presents different considerations than one used for a defined period.

Clinical Implications

Wegovy remains the standard of care for pharmacological weight management in obesity, supported by robust Phase 3 data, extensive real-world experience, and cardiovascular outcomes evidence. Its established safety profile, availability, and insurance coverage (where applicable) make it a well-characterized treatment option.

Retatrutide’s TRIUMPH-4 Phase 3 data have elevated it from a promising Phase 2 candidate to a Phase 3-validated compound with the strongest weight loss efficacy ever demonstrated for a single anti-obesity medication. The -28.7% mean weight loss substantially exceeds Wegovy’s benchmark and approaches the results historically associated with bariatric surgery.

However, efficacy is only one dimension of a drug’s clinical profile. Retatrutide must still demonstrate:

• Consistent safety across the full Phase 3 program
• Long-term durability of weight loss beyond 48 weeks
• Acceptable body composition changes (lean mass preservation)
• Manageable side effect profile in diverse populations
• Cardiovascular safety (and ideally, benefit)

For clinicians and patients currently making treatment decisions, Wegovy is an available, proven option. Retatrutide represents what may be the most significant advance in obesity pharmacotherapy in a decade, but that advance will not reach clinical practice until late 2027 at the earliest. The decision to wait or begin treatment now should be individualized based on clinical urgency, comorbidities, and treatment goals.

Summary of Key Comparisons

Metric	Wegovy	Retatrutide (TRIUMPH-4)
Phase 3 weight loss	-14.9% (68 weeks)	-28.7% (68 weeks)
Weight loss at plateau?	Yes (~60-68 weeks)	Not yet at 48 weeks
Liver fat reduction	~40-50%	~82%
CV outcomes benefit	Yes (20% MACE reduction)	Not studied
Nausea rate	~44%	~24%
Vomiting rate	~24%	~13%
Receptors targeted	GLP-1 only	GIP + GLP-1 + Glucagon
Approval status	FDA-approved (2021)	Phase 3
Oral option	Yes (Rybelsus, lower dose)	No
Earliest availability	Now	Late 2027-2028

Frequently Asked Questions

Is retatrutide better than Wegovy for weight loss?

Phase 3 data strongly suggest greater weight loss with retatrutide. The TRIUMPH-4 trial demonstrated -28.7% mean weight loss at 68 weeks, compared to Wegovy’s -14.9% at 68 weeks in STEP 1. This nearly twofold difference is driven by retatrutide’s additional receptor targets — particularly the glucagon receptor, which increases energy expenditure. However, these are cross-trial comparisons, no head-to-head study exists, and “better” depends on more than efficacy alone. Safety, availability, cardiovascular outcomes, and cost all factor into treatment decisions.

When will retatrutide be available as an alternative to Wegovy?

Retatrutide is in Phase 3 clinical trials and has not been submitted for regulatory approval. The earliest realistic timeline for FDA approval is late 2027 to 2028. Patients currently considering obesity treatment should not delay starting an approved therapy like Wegovy in anticipation of retatrutide. If retatrutide is eventually approved, patients could potentially transition to it under medical supervision.

Does retatrutide have fewer side effects than Wegovy?

Phase 2 data showed retatrutide had numerically lower rates of individual GI adverse events (nausea ~24% vs. ~44%, vomiting ~13% vs. ~24%) compared to Wegovy, despite producing greater weight loss. However, cross-trial adverse event comparisons are unreliable due to differences in reporting, dose-escalation protocols, and study duration. Phase 3 data will provide a clearer picture. The key safety consideration is that Wegovy has years of real-world data confirming its safety profile, while retatrutide’s long-term safety is still being characterized.

Can I switch from Wegovy to retatrutide?

Not currently — retatrutide is investigational and not available by prescription. If it is eventually approved, switching from Wegovy would be a decision made with your physician. The drugs have overlapping but different receptor profiles: retatrutide activates GIP and glucagon receptors in addition to the GLP-1 pathway targeted by Wegovy. A dose titration period would likely be needed. No clinical data on switching protocols currently exist.

Which drug is better for fatty liver — retatrutide or Wegovy?

Retatrutide appears to have a significant advantage. Phase 2 data showed approximately 82% relative liver fat reduction with retatrutide, compared to roughly 40-50% with semaglutide (the active ingredient in Wegovy) in MASLD studies. This difference is attributed to retatrutide’s glucagon receptor activity, which directly stimulates fat oxidation in liver cells. For patients with metabolic dysfunction-associated steatotic liver disease (MASLD), this could be the most important clinical distinction between the two drugs.

Does Wegovy have any advantages over retatrutide?

Yes, several. Wegovy is FDA-approved and available now. It has proven cardiovascular benefit from the SELECT trial (20% reduction in major cardiovascular events). It has years of real-world safety data across millions of patients. An oral formulation exists (Rybelsus, at lower doses for diabetes). Insurance coverage frameworks are established. And its single-receptor mechanism is well characterized. Retatrutide may ultimately prove to be a more potent weight loss agent, but Wegovy’s clinical maturity, accessibility, and cardiovascular evidence provide tangible advantages that will remain relevant even after retatrutide reaches the market.